Side effects associated with psychotropic medications in patients with bipolar disorder: Evidence from two independent samples

Journal of Psychopharmacology

Volumn 27, Issue 7, 2013, Pages 616-628

  Serretti, Alessandro ^a   Chiesa, Alberto ^a,b   Calati, Raffaella ^c   Fabbri, Chiara ^a   Sentissi, Othman ^d   De Ronchi, Diana ^a   Mendlewicz, Julien ^e   Souery, Daniel ^e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

antidepressants; antipsychotics; anxiolytics; bipolar disorder; mood stabilizers; Side effects

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ADULT; ARTICLE; AUTONOMIC NEUROPATHY; BIPOLAR DISORDER; CLINICAL ASSESSMENT TOOL; CLINICAL OUTCOME AND PSYCHO-EDUCATION FOR BIPOLAR DISORDER; CONCENTRATION DIFFICULTY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; SEDATION; SIDE EFFECT; SYSTEMATIC TREATMENT ENHANCEMENT PROGRAM FOR BIPOLAR DISORDER; UDVALG FOR KLINISKE UNDERSOGELSER SIDE EFFECT RATING SCALE;

ANTIDEPRESSANTS; ANTIPSYCHOTICS; ANXIOLYTICS; BIPOLAR DISORDER; MOOD STABILIZERS; SIDE EFFECTS;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 84879398520     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113485143     Document Type: Article

References (48)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Washington, DC: American Psychiatric Association.
2. Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: Risks and management. CNS Spectr. 2006 ; 11: 465-471
3. Bauer MS. A review of quantitative studies of adherence to mental health clinical practice guidelines. Harv Rev Psychiatry. 2002 ; 10: 138-153
4. Berk M, Berk L. Mood stabilizers and treatment adherence in bipolar disorder: Addressing adverse events. Ann Clin Psychiatry. 2003 ; 15: 217-224
5. Brooks JO, Goldberg JF, Ketter TA, et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: Findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry. 2011 ; 72: 240-247
6. Calabrese JR, Elhaj O, Gajwani P, et al. Clinical highlights in bipolar depression: Focus on atypical antipsychotics. J Clin Psychiatry. 2005 ; 66: S26 - S33
7. Canas F, Moller HJ. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: Safety and tolerability review. Expert Opin Drug Saf. 2010 ; 9: 683-697
8. Cohen J Statistical Power Analysis for the Behavioral Sciences. Hillsdale, New Jersey: Lawrence Erlbaum Associates ; 1988 :
9. Connolly KR, Thase ME. The clinical management of bipolar disorder: A review of evidence-based guidelines. Prim Care Companion CNS Disord. 2011 ; 13 :
10. De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: A systematic review and meta-analysis. J Psychopharmacol. 2012 ; 26: 603-617
11. De Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005 ; 66: 15-27
12. Demyttenaere K, Albert A, Mesters P, et al. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?. J Clin Psychiatry. 2005 ; 66: 859-863
13. Dennehy EB, Bauer MS, Perlis RH, et al. Concordance with treatment guidelines for bipolar disorder: Data from the systematic treatment enhancement program for bipolar disorder. Psychopharmacol Bull. 2007 ; 40: 72-84
14. Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010 ;:
15. Fountoulakis KN, Kasper S, Andreassen O, et al. Efficacy of pharmacotherapy in bipolar disorder: A report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2012 ; 262: S1 - S48
16. Gallego JA, Nielsen J, De Hert M, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012 ; 11: 527-542
17. Gelenberg AJ, Jefferson JW. Lithium tremor. J Clin Psychiatry. 1995 ; 56: 283-287
18. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: Part III: Clinical safety. CNS Drugs. 2009 ; 23: 397-418
19. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2000 ; 61: 638-642
20. Hirschfeld RM. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry. 2003 ; 64: S15 - S21
21. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry. 2003 ; 64: 53-59
22. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the national comorbidiy survey replication (NCS-R). JAMA. 2003 ; 289: 3095-3105
23. Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010 ;:
24. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008 ; 34: 60-71
25. Lader M. Some adverse effects of antipsychotics: Prevention and treatment. J Clin Psychiatry. 1999 ; 60: S18 - S21
26. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs. 2006 ; 20: 29-42
27. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987 ; 334: 1-100
28. MacQueen G, Young T. Cognitive effects of atypical antipsychotics: Focus on bipolar spectrum disorders. Bipolar Disord. 2003 ; 5: S53 - S61
29. Meltzer HY, Bobo WV. Interpreting the efficacy findings in the CATIE study: What clinicians should know. CNS Spectr. 2006 ; 11: 14-24
30. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007 ; 64: 543-552
31. Miller DS, Yatham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J Clin Psychiatry. 2001 ; 62: 975-980
32. Nivoli AM, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: A systematic review. J Affect Disord. 2011 ; 129: 14-26
33. Nivoli AM, Murru A, Goikolea JM, et al. New treatment guidelines for acute bipolar mania: A critical review. J Affect Disord. 2012 ; 140: 125-141
34. Papakostas GI. The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry. 2010 ; 71: e03
35. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2010 ; 123: 225-233
36. Sachs GS, Guille C, McMurrich SL. A clinical monitoring form for mood disorders. Bipolar Disord. 2002 ; 4: 323-327
37. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007 ; 356: 1711-1722
38. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003 ; 53: 1028-1042
39. Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry. 1999 ; 38: 44-51
40. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998 ; 59: S22 34 - S33 57
41. Solomon DA, Keitner GI, Ryan CE, et al. Polypharmacy in bipolar I disorder. Psychopharmacol Bull. 1996 ; 32: 579-587
42. Souery D, Zaninotto L, Calati R, et al. Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features. J Affect Disord. 2011 ; 135: 241-250
43. Souery D, Zaninotto L, Calati R, et al. Depression across mood disorders: Review and analysis in a clinical sample. Compr Psychiatry. 2012 ; 53: 24-38
44. Ten Have M, Vollebergh W, Bijl R, et al. Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilisation): Results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord. 2002 ; 68: 203-213
45. Uzun S, Kozumplik O, Jakovljevic M, et al. Side effects of treatment with benzodiazepines. Psychiatr Danub. 2010 ; 22: 90-93
46. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009 ; 70: S1 47 - S46; quiz 47-48.
47. Watson D. Intraindividual and interindividual analyses of positive and negative affect: Their relation to health complaints, perceived stress, and daily activities. J Pers Soc Psychol. 1988 ; 54: 1020-1030
48. Zetin M, Hoepner CT, Bjornson L. Rational antidepressant selection: Applying evidence-based medicine to complex real-world patients. Psychopharmacol Bull. 2006 ; 39: 38-104